At ASCO 2019, Dr. Oliver Sartor gave a presentation on the final PROCEED registry data which tracked Overall Survival (OS) of African American (AA) and Caucasian (CAU) men with mCRPC after receiving Provenge (sipuleucel-T).
The median overall survival (OS) for AA patients was 35.2 months and the median OS for CAU patients was 25.8 months. And it appears that the lower your PSA is at the time of initiation of Provenge therapy, the longer will be the OS time. For the lowest PSA quartile, which were the men with a PSA of less than 8 ng/ml, the median OS for AA men was 54.3 months and for CAU men, the OS was 37.4 months. So why do I say that Provenge is looking better than ever? Because the “registry trial” for Provenge, the one which prompted the FDA to approve Provenge in 2010, the median OS was calculated to be just 4.1 months. The bottom line here is that you should try to get Provenge as soon as you learn you are metastatic castrate resistant (mCRPC).
To read the full article, click here: http://tiny.cc/Provenge